The University of Queensland’s technology transfer company, UniQuest, will partner with the biotechnology company CSL Limited to develop and commercialize the university’s antigen specific immune tolerance induction (ASITI) technology for the treatment of Sjogren’s syndrome. As an autoimmune disorder, Sjogren’s syndrome involves the immune system…
News
Luminary Therapeutics will collaborate with researchers at Case Western Reserve University to develop a new form of CAR T-cell therapy that uses the B-cell activating factor (BAFF) target as a treatment for Sjogren’s syndrome and mantle cell lymphoma. The…
A new study has uncovered two potential biomarkers of primary Sjögren’s syndrome (pSS): progranulin (PGRN) and Oxford 40 ligand (OX40L). People with pSS have higher levels of these two proteins compared to healthy volunteers. The study, “Clinical Significance of Progranulin Correlated With Serum Soluble Oxford 40 Ligand in Primary Sjögren’s…
Researchers have discovered the mechanisms by which Bcl-6 — a protein that is considered a “master regulator” of the immune system — controls the activity of a subset of immune T-cells involved in a range of disorders. According to researchers, knowledge of these mechanisms may prompt the development of…
People with primary Sjögren’s syndrome (pSS) have significantly higher levels of CD72 — a regulatory protein on B-cells, a type of immune cell associated with pSS — than healthy peers, according to a study from China. Data also highlighted an association between CD72 levels and those of IgG —…
A Phase 4 clinical trial evaluating Wize Pharma‘s LO2A eye drops as a treatment for dry eye symptoms in people with Sjögren’s syndrome has been completed, the company announced. Results from the trial are expected later this year, though they may be delayed due to the ongoing…
Genetic variations in the complement system — a part of the immune response — contribute to differences between men and women in their susceptibility to Sjögren’s syndrome, lupus, and schizophrenia, according to a study. In particular, the study showed that higher levels of complement component 4…
A small RNA molecule may help to drive inflammation in the eyes of people with primary Sjögren’s syndrome (pSS), a new study reports. The findings imply that this molecule, called miR-744-5p, may be a therapeutic target for pSS. The study, “miR-744-5p contributes to ocular inflammation in…
In addition to dry eyes, people with Sjögren syndrome have damage to the surface of their eyes, and those with most extensive damage have high levels of biomarkers linked to inflammation, a study found. People whose syndrome is related to…
While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their homes, one may be a new appreciation of telemedicine. “If something good could come out of this crisis, it’s that…
Recent Posts
- Childhood-onset Sjögren’s can cause lasting damage to organs: Study
- Salivary duct treatment eases dry mouth in Sjögren’s disease: Study
- 4 genes linked to inflammatory cell death very active in Sjögren’s
- AI can see what doctors miss to accurately diagnose Sjögren’s
- Worse fatigue tied to more pain in people with Sjögren’s, study finds
- Dazodalibep therapy now in Phase 3 testing for Sjögren’s disease
- Sjögren’s treatment ianalumab shows rapid disease relief in trials
- Sjögren’s patients on nipocalimab report less pain, dryness in trial
- Ouro starts Phase 1b trial of OM336 for Sjögren’s disease treatment
- Telitacicept eases Sjögren’s disease activity in Phase 3 trial